Medical research

Scientists develop antidote to new anticoagulants

(Medical Xpress)—Anticoagulants have saved the lives of those at risk for heart attack or stroke. However, because they prevent blood clotting, they can be dangerous to patients who suffer traumatic injuries or who require ...

Cardiology

New anti-clotting drugs linked to lower risk of serious bleeding

New drugs known as direct oral anticoagulants (DOACs) used to treat serious blood clots are associated with reduced risks of major bleeding compared with the older anti-clotting drug, warfarin, finds a study in The BMJ today.

Cardiology

Interruption of apixaban doesn't impact bleeding in A-fib

(HealthDay)—For patients undergoing catheter ablation for nonvalvular atrial fibrillation (AF), both uninterrupted and minimally interrupted apixaban are associated with a very low rate of thromboembolic events, according ...

Diseases, Conditions, Syndromes

Lower risk of gastrointestinal bleeding for apixaban

(HealthDay)—For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, ...

Cardiology

Non-vitamin K oral anticoagulants vary in assay effects

(HealthDay)—Non-vitamin K oral anticoagulants exhibit variable effects on coagulation assays, according to a study published in the Sept. 16 issue of the Journal of the American College of Cardiology.

Diseases, Conditions, Syndromes

ISTH: Apixaban non-inferior to conventional treatment for VTE

(HealthDay)—For patients with venous thromboembolism, treatment with oral apixaban is non-inferior to conventional therapy for preventing recurrent venous thromboembolism or death related to venous thromboembolism, according ...

page 1 from 2